TWI449525B - 治療癌症之相乘醫藥組合 - Google Patents
治療癌症之相乘醫藥組合 Download PDFInfo
- Publication number
- TWI449525B TWI449525B TW097116343A TW97116343A TWI449525B TW I449525 B TWI449525 B TW I449525B TW 097116343 A TW097116343 A TW 097116343A TW 97116343 A TW97116343 A TW 97116343A TW I449525 B TWI449525 B TW I449525B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- cancer
- doxorubicin
- hours
- treatment
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 135
- 206010028980 Neoplasm Diseases 0.000 title claims description 65
- 201000011510 cancer Diseases 0.000 title claims description 51
- 230000002195 synergetic effect Effects 0.000 title description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 254
- 229960004679 doxorubicin Drugs 0.000 claims description 126
- 239000002246 antineoplastic agent Substances 0.000 claims description 54
- 150000001875 compounds Chemical class 0.000 claims description 41
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 40
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 40
- 229930012538 Paclitaxel Natural products 0.000 claims description 39
- 229960001592 paclitaxel Drugs 0.000 claims description 39
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 37
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 34
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 33
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 33
- 229960005277 gemcitabine Drugs 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 28
- 231100000433 cytotoxic Toxicity 0.000 claims description 26
- 230000001472 cytotoxic effect Effects 0.000 claims description 26
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 19
- 229960003668 docetaxel Drugs 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- QLUYMIVVAYRECT-OCCSQVGLSA-N 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one Chemical compound OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O QLUYMIVVAYRECT-OCCSQVGLSA-N 0.000 claims 1
- 239000004100 Oxytetracycline Substances 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- 229940091658 arsenic Drugs 0.000 claims 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims 1
- 229960000625 oxytetracycline Drugs 0.000 claims 1
- 235000019366 oxytetracycline Nutrition 0.000 claims 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 164
- 229940126062 Compound A Drugs 0.000 description 115
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 114
- 239000003814 drug Substances 0.000 description 63
- 229940079593 drug Drugs 0.000 description 61
- 230000006907 apoptotic process Effects 0.000 description 44
- 239000002609 medium Substances 0.000 description 36
- 238000000034 method Methods 0.000 description 29
- 230000022131 cell cycle Effects 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 230000003013 cytotoxicity Effects 0.000 description 21
- 231100000135 cytotoxicity Toxicity 0.000 description 21
- 229940043239 cytotoxic antineoplastic drug Drugs 0.000 description 17
- 238000011084 recovery Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 12
- 229950010159 nemorubicin Drugs 0.000 description 12
- 230000035899 viability Effects 0.000 description 12
- 229940127071 cytotoxic antineoplastic agent Drugs 0.000 description 10
- -1 galaxie Chemical compound 0.000 description 10
- 239000012453 solvate Substances 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 8
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 101150012716 CDK1 gene Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108050008874 Annexin Proteins 0.000 description 4
- 102000000412 Annexin Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 229940009456 adriamycin Drugs 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 229960003528 flurazepam Drugs 0.000 description 4
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000005265 lung cell Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
- 102000016736 Cyclin Human genes 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 108010040476 FITC-annexin A5 Proteins 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 230000010190 G1 phase Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 229960003260 chlorhexidine Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000003910 Cyclin D Human genes 0.000 description 2
- 108090000259 Cyclin D Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 102000036203 calcium-dependent phospholipid binding proteins Human genes 0.000 description 2
- 108091011005 calcium-dependent phospholipid binding proteins Proteins 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229940127084 other anti-cancer agent Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000004634 pharmacological analysis method Methods 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 210000002706 plastid Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000566113 Branta sandvicensis Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 241000015728 Taxus canadensis Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 244000195452 Wasabia japonica Species 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 229940043241 conventional cytotoxic antineoplastic drug Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 201000003707 ovarian clear cell carcinoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QZWHWHNCPFEXLL-UHFFFAOYSA-N propan-2-yl n-[2-(1,3-thiazol-4-yl)-3h-benzimidazol-5-yl]carbamate Chemical compound N1C2=CC(NC(=O)OC(C)C)=CC=C2N=C1C1=CSC=N1 QZWHWHNCPFEXLL-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2007/051841 WO2008139271A2 (fr) | 2007-05-15 | 2007-05-15 | Combinaison pharmaceutique synergique pour le traitement du cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200913991A TW200913991A (en) | 2009-04-01 |
| TWI449525B true TWI449525B (zh) | 2014-08-21 |
Family
ID=40002696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW097116343A TWI449525B (zh) | 2007-05-15 | 2008-05-02 | 治療癌症之相乘醫藥組合 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8822526B2 (fr) |
| EP (1) | EP2154971B1 (fr) |
| JP (1) | JP5688288B2 (fr) |
| KR (1) | KR101403100B1 (fr) |
| CN (1) | CN101677567B (fr) |
| AR (1) | AR066564A1 (fr) |
| AT (1) | ATE538652T1 (fr) |
| AU (1) | AU2007353129B2 (fr) |
| BR (1) | BRPI0721626A2 (fr) |
| CA (1) | CA2687204C (fr) |
| DK (1) | DK2154971T3 (fr) |
| ES (1) | ES2380129T3 (fr) |
| IL (1) | IL202014A (fr) |
| MX (1) | MX2009012155A (fr) |
| NZ (1) | NZ581183A (fr) |
| PT (1) | PT2154971E (fr) |
| TW (1) | TWI449525B (fr) |
| WO (1) | WO2008139271A2 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI461194B (zh) | 2009-05-05 | 2014-11-21 | Piramal Entpr Ltd | 吡咯啶取代黃酮作為輻射致敏劑 |
| US20120009203A1 (en) * | 2010-06-29 | 2012-01-12 | Anahid Jewett | Depletion of cancer stem cells |
| US9763982B2 (en) | 2010-06-29 | 2017-09-19 | The Regents Of The University Of California | Depletion of cancer stem cells |
| WO2012069972A1 (fr) | 2010-11-19 | 2012-05-31 | Piramal Life Sciences Limited | Combinaison pharmaceutique pour le traitement du cancer du sein |
| AU2011330733A1 (en) * | 2010-11-19 | 2013-06-06 | Piramal Enterprises Limited | Pharmaceutical combination of paclitaxel and a CDK inhibitor |
| TW201242597A (en) | 2011-03-14 | 2012-11-01 | Piramal Life Sciences Ltd | A synergistic pharmaceutical combination for the treatment of pancreatic cancer |
| TW201300105A (zh) * | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |
| AU2012274990A1 (en) | 2011-06-24 | 2014-02-06 | Piramal Enterprises Limited | Compounds for the treatment of cancers associated with human papillomavirus |
| CN111053768B (zh) * | 2013-07-12 | 2023-12-12 | 皮拉马尔企业有限公司 | 用于治疗黑素瘤的药物组合 |
| HK1251655A1 (zh) | 2015-04-20 | 2019-02-01 | Tolero Pharmaceuticals, Inc. | 通过线粒体分析预测对阿伏西地的应答 |
| KR102608921B1 (ko) | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
| JP7083497B2 (ja) | 2015-08-03 | 2022-06-13 | スミトモ ファーマ オンコロジー， インコーポレイテッド | がんの処置のための併用療法 |
| CA3103604C (fr) | 2016-03-28 | 2023-09-26 | Presage Biosciences, Inc. | Combinaisons pharmaceutiques pour le traitement du cancer |
| WO2018094275A1 (fr) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases |
| US11994511B2 (en) | 2017-04-04 | 2024-05-28 | University Of Miami | Biomarkers indicative of prostate cancer and treatment thereof |
| JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン |
| WO2020018037A2 (fr) * | 2018-03-12 | 2020-01-23 | Yeditepe Universitesi | Agent chimiothérapeutique comprenant une combinaison de dichlorhydrate d'alexidine et de pentahydrate de pentaborate de sodium |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| WO2020191326A1 (fr) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Traitement de la leucémie myéloïde aiguë (aml) après échec du vénétoclax |
| RU2710273C1 (ru) * | 2019-04-24 | 2019-12-25 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Фармацевтическая композиция для лечения злокачественных новообразований |
| CN114767669B (zh) * | 2022-05-20 | 2023-07-04 | 湖南省中医药研究院 | 一种P-gp抑制剂及其提取方法和应用 |
| CN116083566B (zh) * | 2022-09-06 | 2025-10-17 | 复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心) | Cdk14的抑制剂在卵巢癌紫杉醇化疗耐药中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070015802A1 (en) * | 2002-07-08 | 2007-01-18 | Nicholas Piramal India Limited | Inhibitors of cyclin dependent kinases and their use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7271193B2 (en) * | 2002-07-08 | 2007-09-18 | Nicholas Piramal India, Ltd. | Inhibitors of cyclin-dependent kinases and their use |
| TWI331034B (en) * | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| US7915301B2 (en) * | 2002-07-08 | 2011-03-29 | Piramal Life Science Limited | Inhibitors of cyclin dependent kinases and their use |
| JP2006508184A (ja) * | 2002-11-06 | 2006-03-09 | サイクラセル・リミテッド | Ｃｄｋ阻害剤及びゲムシタビンを含む医薬組成物 |
| WO2005055952A2 (fr) * | 2003-12-08 | 2005-06-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions anticancereuses synergiques |
| CA2600797A1 (fr) * | 2005-03-11 | 2006-09-21 | The Regents Of The University Of Michigan | Inhibiteurs de chromen-4-one des elements anti-apoptotiques de la famille bcl-2 et utilisations |
-
2007
- 2007-05-15 EP EP07735911A patent/EP2154971B1/fr not_active Not-in-force
- 2007-05-15 PT PT07735911T patent/PT2154971E/pt unknown
- 2007-05-15 CN CN2007800529954A patent/CN101677567B/zh not_active Expired - Fee Related
- 2007-05-15 ES ES07735911T patent/ES2380129T3/es active Active
- 2007-05-15 JP JP2010507996A patent/JP5688288B2/ja not_active Expired - Fee Related
- 2007-05-15 AU AU2007353129A patent/AU2007353129B2/en not_active Ceased
- 2007-05-15 WO PCT/IB2007/051841 patent/WO2008139271A2/fr not_active Ceased
- 2007-05-15 NZ NZ581183A patent/NZ581183A/en not_active IP Right Cessation
- 2007-05-15 MX MX2009012155A patent/MX2009012155A/es active IP Right Grant
- 2007-05-15 BR BRPI0721626-2A patent/BRPI0721626A2/pt not_active IP Right Cessation
- 2007-05-15 KR KR1020097025837A patent/KR101403100B1/ko not_active Expired - Fee Related
- 2007-05-15 AT AT07735911T patent/ATE538652T1/de active
- 2007-05-15 DK DK07735911.5T patent/DK2154971T3/da active
- 2007-05-15 CA CA2687204A patent/CA2687204C/fr active Active
- 2007-05-15 US US12/600,019 patent/US8822526B2/en active Active
-
2008
- 2008-05-02 TW TW097116343A patent/TWI449525B/zh not_active IP Right Cessation
- 2008-05-14 AR ARP080102040A patent/AR066564A1/es unknown
-
2009
- 2009-11-09 IL IL202014A patent/IL202014A/en not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070015802A1 (en) * | 2002-07-08 | 2007-01-18 | Nicholas Piramal India Limited | Inhibitors of cyclin dependent kinases and their use |
Also Published As
| Publication number | Publication date |
|---|---|
| AR066564A1 (es) | 2009-08-26 |
| NZ581183A (en) | 2012-03-30 |
| AU2007353129B2 (en) | 2014-02-20 |
| WO2008139271A2 (fr) | 2008-11-20 |
| IL202014A (en) | 2014-06-30 |
| DK2154971T3 (da) | 2012-04-02 |
| CA2687204C (fr) | 2015-11-24 |
| IL202014A0 (en) | 2010-06-16 |
| EP2154971B1 (fr) | 2011-12-28 |
| CN101677567A (zh) | 2010-03-24 |
| US20100305057A1 (en) | 2010-12-02 |
| EP2154971A2 (fr) | 2010-02-24 |
| JP5688288B2 (ja) | 2015-03-25 |
| CN101677567B (zh) | 2013-06-19 |
| KR20100017763A (ko) | 2010-02-16 |
| KR101403100B1 (ko) | 2014-06-19 |
| MX2009012155A (es) | 2010-01-15 |
| TW200913991A (en) | 2009-04-01 |
| US8822526B2 (en) | 2014-09-02 |
| CA2687204A1 (fr) | 2008-11-20 |
| AU2007353129A1 (en) | 2008-11-20 |
| PT2154971E (pt) | 2012-04-10 |
| JP2010526862A (ja) | 2010-08-05 |
| ATE538652T1 (de) | 2012-01-15 |
| EP2154971A4 (fr) | 2010-05-19 |
| BRPI0721626A2 (pt) | 2013-01-22 |
| WO2008139271A3 (fr) | 2009-04-23 |
| ES2380129T3 (es) | 2012-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI449525B (zh) | 治療癌症之相乘醫藥組合 | |
| RU2438664C2 (ru) | Синергическая фармацевтическая комбинация для лечения рака | |
| CN115996716A (zh) | Eif4a抑制剂组合 | |
| Hasim et al. | Activating transcription factor 3 as a novel regulator of chemotherapy response in breast cancer | |
| TW201330845A (zh) | 胰臟癌及／或膽道癌治療劑 | |
| EP2968379A1 (fr) | Étoposide et leurs promédicaments pour l'utilisation dans le ciblage de cellules souches cancéreuses | |
| KR20200083532A (ko) | 적어도 1종의 스플라이세오솜 조정제, 및 bcl2 억제제, bcl2/bclxl 억제제 및 bclxl 억제제로부터 선택된 적어도 1종의 억제제를 포함하는 조합물 및 사용 방법 | |
| Wang et al. | YC-1 [3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl Indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells | |
| US20220313702A1 (en) | Oxathiazin compounds for inhibiting gapdh | |
| US20100226919A1 (en) | Antitumoral Treatments | |
| JP7388702B2 (ja) | 抗腫瘍剤及び配合剤 | |
| RU2783239C2 (ru) | Комбинация, включающая по меньшей мере один модулятор сплайсосомы и по меньшей мере один ингибитор, выбранный из ингибиторов bcl2, ингибиторов bcl2/bclxl и ингибиторов bclxl, а также способы применения | |
| US20230039766A1 (en) | Combination therapy | |
| WO2022234110A1 (fr) | Dérivés d'acide gamma-aminobutyrique destinée à être utilisée en cancérothérapie | |
| KR20230092999A (ko) | 감마 하위단위 예방 전이를 표적화하는 미토콘드리아 atp 억제제 | |
| TW201307330A (zh) | 治療乳腺癌之藥物組合 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |